Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease I: Introduction01:25

Peptic Ulcer Disease I: Introduction

Peptic ulcer disease (PUD) involves breaks in the gastrointestinal tract's mucosal lining, primarily in the stomach and duodenum, with less frequent occurrences in the lower esophagus or near the pylorus.Ulcers can be acute or chronic. Acute ulcers are short-lived with minimal inflammation and heal quickly after the irritant is removed. Chronic ulcers persist, may recur, and often cause scarring due to ongoing tissue damage. Superficial erosions affect only the mucosal layer and are called...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
Peptic Ulcer01:27

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peptic ulcer disease.

Current opinion in gastroenterology·2006
Same author

The management of peptic ulcer disease.

Current opinion in gastroenterology·2005
Same author

Peptic ulcer disease.

Current opinion in gastroenterology·2005
See all related articles

Related Experiment Video

Updated: Jul 19, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

Peptic ulcer disease.

Japie A Louw1

  • 1Division of Gastroenterology, Queen's University/Hotel Dieu Hospital, Kingston, Ontario, Canada. louwj@hdh.kari.net

Current Opinion in Gastroenterology
|October 21, 2006
PubMed
Summary

Recent findings on dyspepsia and peptic ulcer disease offer insights into triaging patients and new treatments for Helicobacter pylori (H. pylori) infections and nonsteroidal anti-inflammatory drug (NSAID) gastropathy.

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Pharmacology

Background:

  • Dyspepsia and peptic ulcer disease remain significant clinical challenges.
  • Both Helicobacter pylori (H. pylori) infection and nonsteroidal anti-inflammatory drug (NSAID) use are major contributors.
  • Recent literature has advanced understanding and management strategies.

Purpose of the Study:

  • To review and contextualize key clinical publications from the past two years.
  • To focus on advances in dyspepsia and peptic ulcer disease management.
  • To cover both H. pylori-related and NSAID-related conditions.

Main Methods:

  • Literature review of clinically important publications.
  • Synthesis of recent findings on dyspepsia and peptic ulcer disease.

Related Experiment Videos

Last Updated: Jul 19, 2026

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
03:05

Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia

Published on: February 16, 2024

  • Interpretation of data relevant to clinical decision-making.

    • Main Results:

    • New insights into triaging dyspeptic patients.
    • Information on novel proton pump inhibitor (PPI) drugs and H. pylori eradication rescue regimens.
    • Discussion of COX-2 inhibitors, NSAID gastropathy prevention, and the safety of antiplatelet agents.
    • Addressing PPI safety and NSAID enteropathy.

    Conclusions:

    • The review summarizes and interprets recent literature.
    • Provides a foundation for clinical decision-making in dyspepsia and peptic ulcer disease.
    • Highlights evolving strategies for H. pylori and NSAID-related gastrointestinal issues.